The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The relationship between glucocerebrosidase mutations and Parkinson disease
Open accessAbstract
Parkinson disease ( PD ) is the second most common neurodegenerative disorder after Alzheimer disease, whereas Gaucher disease ( GD ) is the most frequent lysosomal storage disorder caused by homozygous mutations in the glucocerebrosidase ( GBA 1 ) gene. Increased risk of developing PD has been observed in both GD patients and carriers. It has been estimated that GBA 1 mutations confer a 20‐ to 30‐fold increased risk for the development of PD , and that at least 7–10% of PD patients have a GBA 1 mutation. To date, mutations in the GBA 1 gene constitute numerically the most important risk factor for PD . The type of PD associated with GBA 1 mutations ( PD ‐ GBA 1 ) is almost identical to idiopathic PD , except for a slightly younger age of onset and a tendency to more cognitive impairment. Importantly, the pathology of PD ‐ GBA 1 is identical to idiopathic PD , with nigral dopamine cell loss, Lewy bodies, and neurites containing alpha‐synuclein. The mechanism by which GBA 1 mutations increase the risk for PD is still unknown. However, given that clinical manifestation and pathological findings in PD ‐ GBA 1 patients are almost identical to those in idiopathic PD individuals, it is likely that, as in idiopathic PD , alpha‐synuclein accumulation, mitochondrial dysfunction, autophagic impairment, oxidative and endoplasmic reticulum stress may contribute to the development and progression of PD ‐ GBA 1 . Here, we review the GBA 1 gene, its role in GD , and its link with PD . image The impact of glucocerebrosidase 1 ( GBA1 ) mutations on functioning of endoplasmic reticulum (ER), lysosomes, and mitochondria. GBA1 mutations resulting in production of misfolded glucocerebrosidase (GCase) significantly affect the ER functioning. Misfolded GCase trapped in the ER leads to both an increase in the ubiquitin–proteasome system (UPS) and the ER stress. The presence of ER stress triggers the unfolded protein response (UPR) and/or endoplasmic reticulum‐associated degradation (ERAD). The prolonged activation of UPR and ERAD subsequently leads to increased apoptosis. The presence of misfolded GCase in the lysosomes together with a reduction in wild‐type GCase levels lead to a retardation of alpha‐synuclein degradation via chaperone‐mediated autophagy (CMA), which subsequently results in alpha‐synuclein accumulation and aggregation. Impaired lysosomal functioning also causes a decrease in the clearance of autophagosomes, and so their accumulation. GBA1 mutations perturb normal mitochondria functioning by increasing generation of free radical species (ROS) and decreasing adenosine triphosphate (ATP) production, oxygen consumption, and membrane potential. GBA1 mutations also lead to accumulation of dysfunctional and fragmented mitochondria. This article is part of a special issue on Parkinson disease .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Self-citationMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Toplak, M. E., Jain, U., & Tannock, R. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-8 · Cited by 303
Cited by
Mitochondrial dysfunction in Parkinson's disease
Bose, A., & Beal, M. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13731 · Cited by 841
Parkinson’s Disease in Women and Men: What’s the Difference?
Cerri, S., Mus, L., & Blandini, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191683 · Cited by 800
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Schöndorf, D. C., Ivanyuk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., Giunta, I., Schwarz, L. K., Di Napoli, G., Panagiotakopoulou, V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.009 · Cited by 337
Metadata
- Authors
- Migdalska‐Richards, A., & Schapira, A. H. V.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-02-10
- Volume
- 139
- Issue
- S1
- Pages
- 77-90
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2337871602
- Cited by
- 231
- References
- 4
- FWCI
- 19.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.